Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)

NCT02241785 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02241785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02241785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)
Lead sponsor
Biogen
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2014
Completion date
May 2, 2016
Enrollment
47 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis